Ameriprise
DNA icon

Ameriprise’s Ginkgo Bioworks DNA Stock Holding History

Ameriprise’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,199
Closed -$253K – 4139
2026
Q1 		$253K Sell
41,199
-8,079
-16% -$67.2K ﹤0.01% 3810
2025
Q4 		$410K Buy
+49,278
New +$531K ﹤0.01% 3698
2024
Q3 		– Sell
-807
Closed -$10.8K – 3952
2024
Q2 		$10.8K Sell
807
-1,004
-55% -$30K ﹤0.01% 3850
2024
Q1 		$84K Sell
1,811
-313
-15% -$16.2K ﹤0.01% 3790
2023
Q4 		$144K Sell
2,124
-8
-0.4% -$490 ﹤0.01% 3771
2023
Q3 		$154K Sell
2,132
-585
-22% -$46.8K ﹤0.01% 3730
2023
Q2 		$202K Sell
2,717
-44
-2% -$2.6K ﹤0.01% 3727
2023
Q1 		$147K Buy
2,761
+461
+20% +$29.2K ﹤0.01% 3787
2022
Q4 		$155K Sell
2,300
-261
-10% -$24K ﹤0.01% 3749
2022
Q3 		$320K Buy
2,561
+2,143
+513% +$255K ﹤0.01% 3560
2022
Q2 		$40K Buy
+418
New +$51K ﹤0.01% 3835

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Ameriprise's DNA Position: Q2 2026 in Review

Ameriprise sold out of Ginkgo Bioworks (DNA) in Q2 2026, closing a stake of 41,199 shares — an estimated $253K sold.

Ameriprise first reported a position in DNA in Q2 2022 and held it in 11 quarters. The position peaked at $410K in Q4 2025. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Ameriprise reported no remaining Ginkgo Bioworks position as of Q2 2026 after selling out during the quarter.
  • Ameriprise sold 41,199 Ginkgo Bioworks shares in Q2 2026, an estimated $253K.
  • Ameriprise first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 11 quarters.
  • Ameriprise's Ginkgo Bioworks position peaked at $410K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.